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 Reporting of Randomized Controlled Trials in Hodgkin 
Lymphoma in Biomedical Journals 
 Thilo  Kober ,  Sven  Trelle ,  Andreas  Engert 
 Background : Randomized controlled trials (RCTs) are the best 
tool to evaluate the effectiveness of clinical interventions. The 
Consolidated Standards for Reporting Trials (CONSORT) 
statement was introduced in 1996 to improve reporting of 
RCTs. We aimed to determine the extent of ambiguity and 
reporting quality as assessed by adherence to the CONSORT 
statement in published reports of RCTs involving patients with 
Hodgkin lymphoma from 1966 through 2002.  Methods : We 
analyzed 242 published full-text reports of RCTs in patients 
with Hodgkin lymphoma. Quality of reporting was assessed 
using a 14-item questionnaire based on the CONSORT check-
list. Reporting was studied in two pre-CONSORT periods 
(1966 – 1988 and 1989 – 1995) and one post-CONSORT period 
(1996 – 2002).  Results : Only six of the 14 items were addressed in 
75% or more of the studies in all three time periods. Most items 
that are necessary to assess the methodologic quality of a study 
were reported by fewer than 20% of the studies. Improvements 
over time were seen for some items, including the description 
of statistics methods used, reporting of primary research 
outcomes, performance of power calculations, method of 
 randomization and concealment allocation, and having per-
formed intention-to-treat analysis.  Conclusions : Despite recent 
improvements, reporting levels of CONSORT items in RCTs 
involving patients with Hodgkin lymphoma remain unsatisfac-
tory. Further concerted action by journal editors, learned soci-
eties, and medical schools is necessary to make authors even 
more aware of the need to improve the reporting RCTs in 
medical journals to allow assessment of validity of published 
clinical research.  [J Natl Cancer Inst 2006;98:620 – 5] 
 The dissemination of biomedical information and publication 
of research results is integral to scientifi c endeavor and is closely 
linked with the historical development of clinical therapeutic 
 trials, beginning with the recording of medical interventions used 
by the ancient Egyptians (e.g., bandaging and stitching of wounds 
circa 1600  bc  ( 1 ) . One important way to convey and develop sci-
entifi c knowledge is through empirical studies that compare the 
effectiveness of behavioral, biologic, and chemical interventions 
in treating certain medical conditions. 
 Within the hierarchy of clinical studies, the randomized con-
trolled trial (RCT) is considered the gold standard for establish-
ing effectiveness because it minimizes bias in evaluating new 
treatment strategies  ( 2 – 4 ) . RCTs represent a key research activ-
ity with the potential to improve the quality of health care and 
control costs through careful comparison of alternative treat-
ments  ( 5 – 7 ) . However, the fl ood of information available in bio-
medical journals during the past 50 years has been enormous 
and creates problems in a variety of areas, e.g., publication and 
selection bias and retraction of invalid literature  ( 8 , 9 ) . Report-
ing standards provide a way to bring consistency to the litera-
ture and reduce problems that can arise from differences in 
language conventions that depend on type of study and specialty 
area  ( 10 ) . 
 In 1982, DerSimonian et al.  ( 11 ) suggested that the reporting 
of clinical trials could be greatly improved by providing authors 
with a list of items that are expected to be reported. A group of 
journal editors, clinical trialists, and methodologists subsequently 
published a common checklist for items to include in reports of 
RCTs in 1996, known as the Consolidated Standards of Report-
ing Trials (CONSORT) statement. Work on a revised checklist 
started in 1999 that, on completion in 2001  ( 12 ) , featured 22 
items to include when reporting an RCT. Its use is recommended 
by the International Committee of Medical Journal Editors, the 
Council of Science Editors, and the World Association of Medi-
cal Editors  ( 13 ) ; to date, more than 150 biomedical journals, in-
cluding the  Journal of the National Cancer Institute , have 
adopted these recommendations  ( 14 ) . 
 A number of publications have studied the quality of reports 
of RCTs in subspecialties of medicine  ( 15 – 30 ) . However, no 
study, to our knowledge, has investigated RCTs focusing on 
Hodgkin disease alone and analyzed changes in reporting over 
multiple decades. Furthermore, empirical evidence on the qual-
ity assessment of RCTs in the fi eld of medical oncology is scanty. 
In this article, we report the results of our examination of the 
quality of reporting of RCTs involving patients with Hodgkin 
lymphoma in the context of the CONSORT statement. We chose 
this cancer because it is a complex clinical condition that re-
quires sophisticated multimodal interventions and treatment 
schedules. Consequently, clinical trials in Hodgkin lymphoma 
are often conducted by cooperative groups, a setting that is pre-
sumed to be high in quality of design, conduct, and evaluation of 
coordinated trials. In addition, trials in Hodgkin lymphoma have 
been carried out for many years, providing the opportunity to 
study changes in reporting over a relatively long time. 
 M ETHODS 
 Search Strategies and Study Identifi cation 
 Online searches of the Medline, EMBASE, Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), Institute of Sci-
entifi c Information Web of Science (ISI WoS), PsychIndex, 
Allied and Complementary Medicine (AMed), and CancerLit 
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biomedical databases for reports on RCTs involving patients 
with Hodgkin lymphoma were performed through May 2003, 
supplemented by hand searching of reference lists. To ensure 
that we would fi nd as many trials as possible we searched text 
and index words with the truncated version  “ hodgkin*. ” Re-
sults were combined ( “ AND ” ) with the Cochrane Collaboration 
sensitive search strategy for RCTs  ( 31 ) . References were 
screened independently by two persons (S. Trelle and T. Kober) 
for eligibility without language restriction. Trials were eligible 
if they had randomly assigned participants prospectively to at 
least two treatment arms and included patients with Hodgkin 
lymphoma. Trials were classifi ed as reports if they were pub-
lished as full or short papers, editorials, or letters in a regular 
issue or supplement of a biomedical journal or book from 1966 
through 2002. 
 A total of 20  499 potentially eligible references were identi-
fi ed ( Fig. 1 ), of which 10  397 were found to be duplicates. The 
remaining 10  102 unique citations were screened independently 
by two persons (S. Trelle and T. Kober). Inter-rater agreement 
was assessed using the kappa statistic on randomly selected ref-
erences on 16 occasions during the screening process and was 
classifi ed as  “ good ” (median for kappa: 0.6). 
 After eligibility screening, 8809 citations did not fi t the inclu-
sion criteria (e.g., they were RCTs in diseases or conditions other 
than Hodgkin lymphoma; nonrandomized trials, narrative re-
views, or meta-analyses in Hodgkin lymphoma; RCTs in non-
Hodgkin lymphoma; or not relevant to the topic), leaving 1293 
citations requiring complete full-text evaluation. Of those, nine 
(0.7%) could not be retrieved. The remaining 1284 references were 
 obtained in hard copy and screened further. Of these, 814 articles 
were excluded because they also did not fulfi ll the inclusion crite-
ria, leaving 470 citations for additional analysis. Of these, 27 
(5.7%) that were not in English or German were omitted, as was 
one that turned out to be a duplicate. In addition, 200 abstracts 
were not considered further due to their limited information value 
 ( 32 ) . Consequently, a total of 242 reports remained for analysis. 
 Fig. 1.  Flow of citations through the retrieval and 
screening process. CENTRAL = Cochrane Central 
Register of Controlled Trials; ISI WoS = Institute of 
Scientifi c Information Web of Science; AMed = Allied 
and Complementary Medicine; RCT = randomized 
controlled trial; HD = Hodgkin disease. 
References identified:
Medline: n= 3,549
EMBASE: n= 6,464
CENTRAL: n= 1,450
ISI WoS: n= 4,776
Psychindex: n= 290
AMed: n= 94
CancerLit: n= 3,876
n= 20,499
Screened for eligibility: n= 10,102
Excluded
[Non-controlled trials in HD: n=       595 
Other studies in HD: n=    1,809 
Narrative reviews in HD: n=      493 
Systematic reviews in HD: n=        19
RCTs in non-Hodgkin: n=      462 
Not relevant to topic: n=    5,431] 
Total: n=  8,809 
Excluded:
Identified duplicates:           n= 10,397 
Required as full text                       n=                1293
Unable to retrieve                           n=                      9 
References checked  
by full-text: n=      1,284
References retrieved n=        470
(Articles n=       269) 
Duplicate article n=           1  
(Abstracts n=       200) 
Included in final analysis only articles published in
English or German language  
n=   242
Excluded
[Non-controlled trials in HD: n=       223 
Other studies in HD: n=        141 
      27 
Narrative reviews in HD: n=         88 
Systematic reviews in HD: n=           2 
RCTs in non-Hodgkin: n=         31 
Not relevant to topic: n=        329]
Total: n= 
n= 
     814 
Excluded articles requiring but unable to perform
translation    
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 Reporting Assessment Tool 
 A data extraction sheet based on CONSORT reporting items 
was developed. Although all items in the CONSORT checklist are 
considered important to help to improve the quality of reports of 
RCTs, some are more subjective than others (e.g., assessment of 
whether Discussion sections of manuscripts addressed interpret-
ability of results). We did not consider items that are mainly rele-
vant for assessing external validity of a study (e.g., eligibility 
criteria or baseline characteristics) because our aim was to survey 
the reporting level of items that are important to assess potential 
biases. We therefore chose to analyze 13 of the 22 items of the 
CONSORT statement ( Table 1 ). We also analyzed reporting of an 
additional item that is not included in the CONSORT statement, 
namely, confl ict of interest. This item was chosen for its relevance 
in terms to refl ect general transparency in scientifi c writing and was 
adopted from  The Lancet as an acceptable reporting item  ( 33 ) . 
 Items were investigated in terms of whether they were re-
ported, not whether they were actually carried out during the trial. 
Response alternatives to each question were: yes, no, unclear, 
and not applicable (NA). Unclear and NA responses were both 
coded as missing data. 
 Statistical Methods 
 Reporting items to be evaluated were derived from the data 
extraction sheet and analyzed with Stata (Version 9.1) by descrip-
tive summary statistics and exact confi dence intervals. To test 
for reporting differences over time, reports were grouped in three 
publication periods, i.e., 1966 – 1988 (pre-CONSORT 1), 1989 –
 1995 (pre-CONSORT 2), and 1996 – 2002 (post-CONSORT). The 
cut points for time periods were chosen to refl ect the low number 
of publications in the mid-1960s to mid-1970s. The average an-
nual publication rate of RCTs in Hodgkin lymphoma increased 
from 1.25 publications per year for the period 1966 – 1974 to 14.6 
for the period 1996 – 2002, representing a mean increase of ap-
proximately eight publications each year over the entire period 
under investigation. Because discussions about reporting quality 
of trials increased in the 1980s  ( 11 , 12 ) , we used a second 
pre-CONSORT period to investigate possible changes that 
 occurred before the introduction of CONSORT. 
 Comparisons among periods were made using a chi-square 
test for trend. Clustering of articles in a journal or by study group 
was not taken into account in the analyses. The cutoff point for 
statistical signifi cance was set at the two-sided .05 level. No ad-
justments for multiple comparisons were used because of the 
 exploratory nature of the hypotheses tests. 
 R ESULTS 
 Of the 242 study reports that we analyzed, 83 were pub-
lished in 1966 – 1988 (pre-CONSORT 1), 70 in 1989 – 1995 (pre-
CONSORT 2, and 89 in 1996 – 2002 (post-CONSORT).  Table 1 
shows the frequency of reporting of the 14 items in our data ex-
traction sheet for each of these three periods and for the com-
bined  period. 
 Only six items were reported by 75% or more of the studies in 
all of the time periods ( Table 1 ). These include reporting of ran-
domization in the title or abstract, descriptions of statistical meth-
ods, description of the scientifi c background and purpose of the 
study, reporting summary results, reporting adverse events, and 
reporting the details of the intended intervention in each group. 
 By contrast, a number of items identifi ed by data extraction 
were reported by only a small percentage of the trials in all three 
periods. For example, only 14% (31 of 226) of reports provided a 
description of the randomization process, although there was 
some improvement after CONSORT was implemented. Simi-
larly, only 30 of 234 articles (13%) provided details about whether 
and how concealment of allocation was carried out. A trend test 
across all three periods showed better reporting of allocation con-
cealment after CONSORT. Only 13% (30 of 235) of all studies 
provided a statement or explanation of how the study power was 
calculated. However, reporting of this information improved in 
the post-CONSORT period. Similarly, although only a small 
number of studies (28 of 241, or 12%) stated the performed data 
analysis explicitly as intention-to-treat, reporting of this item also 
showed a statistically signifi cant improvement after CONSORT. 
 Table 1.  Frequency of reporting of 14 data items in a total of 242 randomized clinical trials in Hodgkin lymphoma by publication period 
(pre- and post-CONSORT and combined) * 
Data item
Combined 1966 – 2002 
( n = 242) † 
Pre-CONSORT 1 
1966 – 1988 ( n = 83)
Pre-CONSORT 2 
1989 – 1995 ( n = 70)
Post-CONSORT 
1996 – 2002 ( n = 89)
 
P for trend ‡ 
Power calculation 30/235; 13% (9% to 18%) 1/81 (1%) 9/69 (13%) 10/85 (12%) .030
Intention to treat 28/241; 12% (8% to 16%) 0/83 (0%) 7/70 (10%) 21/88 (24%) <.001
Primary outcomes 105/236; 44% (38% to 51%) 12/80 (15%) 32/69 (46%) 61/87 (70%) <.001
Precision of estimated effect size 52/240; 22% (17% to 27%) 4/82 (5%) 9/69 (13%) 39/89 (44%) <.001
Statistical methods 199/240; 83% (78% to 87%) 63/83 (76%) 55/70 (79%) 81/87 (93%) .003
Randomized in title/abstract 211/242; 87% (82% to 91%) 65/83 (78%) 63/70 (90%) 83/89 (93%) .004
Confl ict of interest 10/240; 4% (2% to 8%) 0/83 (0%) 4/69 (6%) 6/88 (7%) .027
Method of randomization 31/226; 14% (10% to 19%) 7/79 (9%) 8/66 (12%) 16/81 (20%) .045
Concealment of allocation 30/234; 13% (9% to 18%) 5/82 (6%) 11/66 (17%) 14/86 (16%) .050
Withdrawals and dropouts 134/230; 58% (52% to 65%) 42/77 (55%) 37/67 (55%) 55/88 (63%) .294
Scientifi c background and purpose 226/235; 96% (93% to 98%) 75/79 (95%) 68/69 (99%) 83/87 (95%) .901
Summary results 238/240; 99% (97% to 100%) 81/82 (99%) 68/69 (99%) 89/89 (100%) .373
Adverse events 187/227; 82% (77% to 87%) 66/79 (84%) 51/64 (80%) 70/84 (83%) .981
Details of intervention in each arm 231/241; 96% (93% to 98%) 80/83 (96%) 67/70 (96%) 84/88 (95%) .761
 * CI = confi dence interval. CONSORT = Consolidated Standards of Reporting Trials. 
 † The number of articles reporting the item/total number of articles, percentage, and 95% confi dence intervals. Some data are missing for most items (median number 
of reports for which data are missing = 4; range = 0 – 16). 
 ‡ P values were obtained from chi-square tests of associations between proportions for reporting an item and publication period across the three periods. 
Journal of the National Cancer Institute, Vol. 98, No. 9, May 3, 2006 ARTICLES 623
Only 4% of articles (10 of 240) provided a confl ict of interest 
statement. Although there was some improvement over time, it 
was only moderate. Two additional items showed increases in re-
porting frequency after CONSORT. These were explicit re porting 
of primary outcomes and estimates of the precision of estimated 
effect size (i.e., presentation of 95% confi dence intervals). 
 We also performed a stratifi ed analysis according to whether 
journals have or have not adopted the CONSORT statement (data 
not shown). Overall, improvements over time were mostly seen 
in journals not adopting the CONSORT statement. However, the 
number of articles in journals that promote CONSORT was low, 
and reporting quality was already better in the pre-CONSORT 
era in these journals than in journals that did not go on to adopt 
CONSORT. A comparison between journals adopting CONSORT 
and journals not adopting these recommendations for the post-
CONSORT era only showed no difference in reporting quality 
for any of the assessed items (data not shown). 
 Reporting of results according to the intention-to-treat princi-
ple was analyzed in more detail because deviations from this 
principle can lead to overoptimistic and biased results. We there-
fore examined closely the subset of 29 studies that explicitly 
stated that analyses were carried out according to this principle. 
Of these studies, only 17 (59%) appeared to actually analyze par-
ticipants as randomly assigned. 
 D ISCUSSION 
 Our research shows that essential methodologic aspects of 
RCTs are seldom described in published reports, making it im-
possible for the reader to assess their validity. We found statisti-
cally signifi cant improvements over time in some reporting items 
but several important methodologic descriptions (of allocation 
concealment and of the randomization method) improved only 
minimally. Nevertheless, a consistent trend to better reporting 
was observed in all methodologic aspects of study reports. This 
trend started even before the publication of CONSORT and is 
probably related to the increasing discussion about methodologic 
quality of clinical research in the 1980s. The CONSORT state-
ment may be viewed as a result of these discussions and improve-
ments even before its publication. The observed reporting level 
seen in this study may therefore be more related to the general 
scientifi c discussion and less to the publication of CONSORT it-
self. Although the direct impact of CONSORT remains undeter-
mined from this study, it seems clear that CONSORT provides an 
explicit and therefore useful framework for authors and editors. 
Its publication and the preceding discussions may have increased 
awareness on the side of authors and editors, resulting in im-
proved reporting. 
 Data on the quality of reports of RCTs in subspecialties of 
medicine are increasingly available. Although surveys and stud-
ies similar to this one have been conducted previously, this re-
search is the fi rst, to our knowledge, to investigate the reporting 
of RCTs with particular reference to CONSORT for Hodgkin 
lymphoma only, covering a period of almost 40 years. One of the 
fi rst studies to investigate the extent of ambiguous and unclear 
reporting in the medical literature was research undertaken by 
Mulrow et al.  ( 15 ) , which assessed 50 papers published from 
June 1985 to June 1986 in four leading journals based on eight 
explicit information criteria. Of the 50 publications, 17 satisfi ed 
three of the eight criteria, 32 satisfi ed four or fi ve, and one satis-
fi ed six. Moher et al.  ( 27 ) were among the fi rst to investigate 
whether the use of the CONSORT statement was associated with 
an improvement in the quality of reports of RCTs. They com-
pared the quality, as assessed by the number of CONSORT items 
included in the report, of 71 RCTs published in  BMJ, JAMA, 
The Lancet, and  The New England Journal of Medicine in 1994 
(pre-CONSORT) with that of 77 RCTs published in the same 
journals in 1998 (post-CONSORT). For three of the four jour-
nals, statistically signifi cantly more CONSORT checklist items 
were included in RCT reports in 1998 than in 1994 (mean num-
ber pre-CONSORT = 23.4; mean change = 3.7). Devereaux et al. 
 ( 26 ) reported an evaluation of 105 RCT reports published in 29 
biomedical journals. They analyzed the quality of reporting of 11 
key methodologic factors in relation to whether a journal had 
adopted CONSORT. The analysis suggested that articles in 
journals adhering to CONSORT guidelines included a statisti-
cally signifi cantly higher number of reporting factors than those 
in nonpromoter journals ( P = .03). 
 A more recent study, by Mills et al.  ( 14 ) , investigated the 
 extent to which four clinical pharmacology journals had im-
plemented specifi c CONSORT recommendations. Among 193 
RCTs, the following items were reported in the majority of 
 studies: use of intention-to-treat analysis, 79%; description of 
 withdrawals, 92%; description of adverse events, 71%; and 
sources of funding, 56%. By contrast, several items were poorly 
reported: description of method of randomization, 17%, and al-
location concealment, 3%. In an evaluation of reports of RCTs in 
myeloma  ( 25 ) , only 10 of 136 (7%) were analyzed according to 
intention-to-treat principles, 12 of 136 (9%) reported a power 
analysis, 35 of 111 (32%) reported adequately concealed treat-
ment allocation, and 106 of 136 (78%) provided a detailed de-
scription of patient withdrawals. 
 Our study has several limitations. One is that we did not in-
clude all 22 reporting items listed in the CONSORT checklist. 
However, to our knowledge our study included more items than 
any previous study; in addition, we investigated one aspect not 
included in CONSORT, that is, the declaration of any fi nancial or 
personal confl ict of interests. The results in reporting confl ict of 
interest post-CONSORT are, in our view, most likely infl uenced 
by the  Uniform Requirements for Manuscripts Submitted to Bio-
medical Journals, a document developed by the International 
Committee of Medical Editors  ( 34 ) . Another limitation of our 
study was that it was designed only to evaluate the reporting 
quality of RCTs overall and not to assess the quality of the 
 individual study design or to assess how study design affects 
 intervention outcomes  ( 23 , 35 , 36 ) . As empirical research has 
shown, the quality of the trial may well be different from the 
quality of the study report  ( 37 ) . For example, Soares et al.  ( 24 ) 
evaluated the quality of 58 published reports of RCTs completed 
by the Radiation Therapy Oncology Group. This analysis showed 
that only 9% of published reports provided information on sam-
ple size calculation, although this information was available in 
44% of the group’s protocols. Yet another potential limitation is 
that we assessed only publications in English and German, which 
may contribute to introduce publication bias. However, only 10% 
of the eligible articles were reports in other languages, and it is 
unlikely that their inclusion would have changed the overall re-
sults. Another limitation would arise if Hodgkin lymphoma is not 
representative for reporting RCTs in other malignant diseases. 
However, because investigations about reporting quality in other 
medical conditions have reached conclusions similar to ours, we 
624 ARTICLES Journal of the National Cancer Institute, Vol. 98, No. 9, May 3, 2006
believe that RCTs in Hodgkin lymphoma may well be represen-
tative of trials in cancer generally. 
 In summary, our fi ndings indicate that reports of RCTs involv-
ing patients with Hodgkin lymphoma published after 1996 do not 
conform with CONSORT recommendations. Consequently,  users 
of such trial reports may still fi nd it diffi cult to easily identify, 
assess, and synthesize all data required to make a comprehensive 
and thorough judgment about the benefi ts and harms of the inter-
ventions tested. Moreover, the application of the results in clini-
cal practice is hampered if not prevented, because their validity is 
not assessable. 
 Although we did not investigate the relationship between 
CONSORT adherence and study quality or the validity of study 
results since 1996, our study identifi ed an undesirable level of 
ambiguity and uncertainty in the reporting of RCTs. This is par-
ticularly evident in the number of missing responses for most 
data items under investigation, ranging from 1% to 7% ( Table 1 ). 
It is imperative that clinicians be able to maintain up-to-date in-
formation through the scientifi c literature. Hence, clinical trial 
reports should be succinct, comprehensive, and reader-friendly. 
The CONSORT statement and checklist is one major initiative to 
facilitate clear reporting and to provide more transparency in the 
way in which research results are conveyed in biomedical jour-
nals. Thus, our fi ndings strongly support making use of the 
 CONSORT checklist mandatory for all authors reporting on 
RCTs. The onus is on both parties — those who submit manu-
scripts and those who read them during the peer review and pre-
publication stages. Because reporting quality is still low after the 
publication of CONSORT, editors, in particular, should be en-
couraged to scrutinize manuscripts more carefully and to remind 
and guide authors in the use of CONSORT as a prerequisite for 
publication. To foster better reporting, all journal recommenda-
tions for preferred presentation and analysis of data should be 
described in the Information for Contributors or Authors. Wher-
ever possible, recommendations should be based on evidence 
about methods of data presentation, such as CONSORT, that are 
readable and most likely to be interpreted correctly by readers. 
Editors should keep themselves informed of this research and 
adapt their recommendations as it evolves. Empirical evidence 
shows that there is room for improvement on the side of the 
 journals  ( 38 ) . 
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